Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancerPhase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancerPhase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancerRetrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervixPresenters:Susana Banerjee, MBBS, MA, PhD, FRCPConsultant Medical Oncologist and Research LeadGynaecology UnitRoyal Marsden NHS Foundation TrustLondon, United KingdomMansoor Raza Mirza, MDChief OncologistDepartment of OncologyRigshopitalet – Copenhagen University HospitalCopenhagen, DenmarkContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/38xuRBv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.